Marker Therapeutics, Inc. (MRKR)
MRKR Stock Price Chart
Explore Marker Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze MRKR price movements and trends.
MRKR Company Profile
Discover essential business fundamentals and corporate details for Marker Therapeutics, Inc. (MRKR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Jul 2002
Employees
5.00
CEO
Juan F. Vera
Description
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
MRKR Financial Timeline
Browse a chronological timeline of Marker Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.25, while revenue estimate is $682.10k.
Earnings released on 15 May 2026
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%, while revenue for the quarter reached $800.00k , beating expectations by +2.05%.
Earnings released on 18 Mar 2026
EPS came in at -$0.04 surpassing the estimated -$0.21 by +80.95%, while revenue for the quarter reached $1.10m , beating expectations by +61.27%.
Earnings released on 13 Nov 2025
EPS came in at -$0.12 surpassing the estimated -$0.36 by +66.67%, while revenue for the quarter reached $1.23m , beating expectations by +70.53%.
Earnings released on 14 Aug 2025
EPS came in at -$0.29 surpassing the estimated -$0.30 by +4.56%, while revenue for the quarter reached $861.18k , beating expectations by +100.00%.
Earnings released on 21 May 2025
EPS came in at -$0.27 surpassing the estimated -$0.66 by +59.09%, while revenue for the quarter reached $349.10k , beating expectations by +100.00%.
Earnings released on 31 Mar 2025
EPS came in at -$0.42 falling short of the estimated -$0.22 by -90.91%, while revenue for the quarter reached $2.25m , beating expectations by +84.10%.
Earnings released on 14 Nov 2024
EPS came in at -$0.26 surpassing the estimated -$0.39 by +33.33%, while revenue for the quarter reached $1.93m , beating expectations by +92.60%.
Earnings released on 14 Aug 2024
EPS came in at -$0.29 surpassing the estimated -$0.43 by +32.56%, while revenue for the quarter reached $1.17m .
Earnings released on 15 May 2024
EPS came in at -$0.27 falling short of the estimated -$0.25 by -8.00%, while revenue for the quarter reached $1.24m .
Earnings released on 26 Mar 2024
EPS came in at -$0.48 surpassing the estimated -$1.00 by +52.00%, while revenue for the quarter reached $1.06m .
Earnings released on 9 Nov 2023
EPS came in at -$0.34 surpassing the estimated -$0.90 by +62.22%, while revenue for the quarter reached $257.61k .
Earnings released on 14 Aug 2023
EPS came in at -$0.47 surpassing the estimated -$0.80 by +41.25%, while revenue for the quarter reached $762.66k .
Earnings released on 16 May 2023
EPS came in at -$0.57 falling short of the estimated $0.80 by -171.25%, while revenue for the quarter reached $1.23m .
Earnings released on 22 Mar 2023
EPS came in at -$0.48 surpassing the estimated -$1.00 by +52.00%, while revenue for the quarter reached $759.14k , beating expectations by +181.16%.
Stock split effective on 27 Jan 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2022
EPS came in at -$0.80 surpassing the estimated -$1.20 by +33.33%, while revenue for the quarter reached $999.57k , beating expectations by +149.89%.
Earnings released on 11 Aug 2022
EPS came in at -$1.10 surpassing the estimated -$1.27 by +13.39%, while revenue for the quarter reached $790.51k , missing expectations by -68.38%.
Earnings released on 13 May 2022
EPS came in at -$1.20 surpassing the estimated -$1.33 by +9.77%, while revenue for the quarter reached $964.32k , missing expectations by -3.57%.
Earnings released on 17 Mar 2022
EPS came in at -$1.20 surpassing the estimated -$1.27 by +5.51%, while revenue for the quarter reached $1.24m .
Earnings released on 10 Nov 2021
EPS came in at -$1.20 surpassing the estimated -$1.27 by +5.51%.
Earnings released on 10 Aug 2021
EPS came in at -$1.30 falling short of the estimated -$1.17 by -11.11%.
MRKR Stock Performance
Access detailed MRKR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
